FDA rejects new indication for Spectrum drug

The FDA declined to approve a supplementary marketing application for Spectrum Pharmaceuticals' cancer drug Fusilev. Currently approved for bone cancer, the company was hoping it could expand the drug's indications to include advanced metastatic colorectal cancer. Spectrum said it will request a meeting with the agency to discuss further approval of the drug. The company's shares dropped 17 percent this morning on the news. Article

Suggested Articles

Half of patients in an early trial of Allogene's off-the-shelf CAR-T cells for lymphoma who received a higher dose of its antibody ALLO-647 responded.

Takeda is tossing out a Shire pipeline med after it couldn't find a buyer.

Ipsen's new hire arrives at a company reeling from a torrent six months that have crushed hopes for its $1 billion bet on a rare disease drug.